MedTrace Logo

A New Conception About Individualized Treatment Allocation for HCC

NCT06008548 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4991

Last updated 2023-08-23

No results posted yet for this study

Summary

The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider the simultaneous comparison of distinct therapies in similar populations. Here, the investigators aimed to develop and validate a new, integrated prognostic scheme for HCC patients using artificial intelligence (AI) to simulate the survival outcomes of patients allocated to different treatments.

Conditions

  • HCC
  • Transarterial Chemoembolization
  • Resection

Interventions

PROCEDURE

TACE

Sponsors & Collaborators

  • Air Force Military Medical University, China

    collaborator OTHER

  • Army Medical University, China

    collaborator OTHER

  • The First Affiliated Hospital of Shanxi Medical University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Shaanxi Provincial People's Hospital

    collaborator OTHER

  • Xijing Hospital

    collaborator OTHER

  • Xi'an Jiaotong University

    collaborator OTHER

  • Tang-Du Hospital

    lead OTHER

Principal Investigators

  • Lei Liu, doctor · Tangdu Hospital-Air Force Medical University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2021-01-30
Completion
2021-10-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06008548 on ClinicalTrials.gov